Small airways response to bronchodilators as the marker of the uncontrolled asthma in children

Olena Rechkina1, Svitlana Opimakh1, Oksana Kravtsova1

  • 1STATE ORGANIZATION "NATIONAL INSTITUTE OF PHTHISIOLOGY AND PULMONOLOGY NAMED AFTER F.G. YANOVSKY NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE", KYIV, UKRAINE.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|September 6, 2024
PubMed

Insights

Maximal expiratory flow (MEF50 and MEF25) indices can identify small airway obstruction in children with uncontrolled asthma. An increase of 22% (MEF50) or 25% (MEF25) after bronchodilator use indicates uncontrolled asthma.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Asthma Research

Background:

  • Asthma control in children is often assessed using standard spirometry, which may not fully capture small airway dysfunction.
  • Small airways play a crucial role in asthma pathophysiology, and their obstruction can lead to poor disease control.

Purpose of the Study:

  • To establish criteria for small airways response to bronchodilators using spirometry indices (MEF50 and MEF25).
  • To identify these indices as markers for assessing uncontrolled asthma in pediatric populations.

Main Methods:

  • The study included 92 children (aged 6-17 years) diagnosed with asthma.
  • Asthma control was evaluated using the Asthma Control Test and Asthma Control Questionnaire.
  • Spirometry and bronchodilator responsiveness testing were conducted for all participants.

Main Results:

  • Children with uncontrolled asthma often exhibit normal FEV1 but significantly impaired small airway patency.
  • Small airway obstruction is present in up to 80% of children with uncontrolled asthma.
  • MEF50 and MEF25 demonstrated high sensitivity and specificity in identifying bronchial obstruction reversibility and uncontrolled asthma.

Conclusions:

  • MEF50 and MEF25 indices effectively detect small airway obstruction and its reversibility, serving as indicators of uncontrolled asthma.
  • MEF25 shows a higher diagnostic value compared to MEF50.
  • A bronchodilator response of ≥22% for MEF50 or ≥25% for MEF25 suggests uncontrolled asthma in children.
Abstract

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
239
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
374
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
362
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K